Melissa Tache
Family Medicine · Coldwater, MINPI 1689025553
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 465 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,970, more than ten times the $35 reported in 2019. Among family medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 465 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- AstraZeneca$911
- Lilly USA, LLC$678
- Pfizer$440
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$407
- plus $3K from 34 others
What the payments were for
- Food & beverage$8,055100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 74 | $1,250 |
| Novo Nordisk | 76 | $1,038 |
| AstraZeneca | 34 | $911 |
| Lilly USA, LLC | 45 | $678 |
| Pfizer | 23 | $440 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $407 |
| GSK | 33 | $404 |
| Bayer | 21 | $339 |
| Boehringer Ingelheim | 16 | $318 |
| Axsome Therapeutics, Inc. | 10 | $236 |
| Otsuka America Pharmaceutical, Inc. | 8 | $197 |
| Vanda Pharmaceuticals Inc. | 6 | $170 |
| Amgen | 10 | $159 |
| Daiichi Sankyo Inc. | 8 | $154 |
| Exact Sciences | 9 | $148 |
| Novartis | 8 | $131 |
| Lundbeck LLC | 6 | $113 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $109 |
| Johnson & Johnson | 7 | $109 |
| Biohaven Pharmaceuticals, Inc. | 4 | $67 |
| Dexcom, Inc. | 3 | $61 |
| Mylan Specialty L.p. | 3 | $61 |
| UCB, Inc. | 3 | $56 |
| Amarin Pharma, Inc. | 3 | $47 |
| Alkermes, Inc. | 2 | $46 |
| Corcept Therapeutics | 2 | $46 |
| Endologix LLC | 1 | $46 |
| Abbott | 2 | $46 |
| Indivior Inc. | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Inspire Medical Systems, Inc. | 2 | $36 |
| Astellas Pharma US Inc | 1 | $26 |
| Electromed, Inc. | 1 | $19 |
| Viatris Specialty LLC | 1 | $18 |
| Neurelis, Inc. | 1 | $17 |
| Bausch Health US, LLC | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
| Verona Pharma, Inc. | 1 | $14 |
| GRT US Holding, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,055 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $87,971 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $54,088 |
| EliquisApixaban | 60 | $49,622 |
| TrulicityDulaglutide | 42 | $46,407 |
| MounjaroTirzepatide | 40 | $45,915 |
| FarxigaDapagliflozin Propanediol | 34 | $34,535 |
| VraylarCariprazine Hcl | 24 | $33,341 |
| RybelsusSemaglutide | 16 | $29,213 |
| JardianceEmpagliflozin | 21 | $28,887 |
| XareltoRivaroxaban | 31 | $28,211 |
| CaplytaLumateperone Tosylate | 14 | $26,012 |
| MyrbetriqMirabegron | 16 | $19,149 |
| TrintellixVortioxetine Hydrobromide | 16 | $11,412 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $8,301 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $7,925 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,038 | $117,18495 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $678 | $92,32282 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $404 | $62,38976 claims |
| PfizerEliquis | $440 | $49,62260 claims |
| AstraZenecaFarxiga, Symbicort | $911 | $42,46050 claims |
| AbbVieVraylar | $1,250 | $33,34124 claims |
| Boehringer IngelheimJardiance | $318 | $28,88721 claims |
| Johnson & JohnsonXarelto | $109 | $28,21131 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $407 | $26,01214 claims |
| Astellas Pharma US IncMyrbetriq | $26 | $19,14916 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $13 | $11,41216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Coldwater
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Jeffrey DeitchSterling Heights$197K
- Sukhpreet SinghPlymouth$173K
- James VoigtOak Park$140K
- Timothy IzzoGrand Ledge$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.